ProfileGDS5678 / 1440407_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 38% 38% 38% 39% 42% 44% 39% 39% 39% 39% 39% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9153738
GSM967853U87-EV human glioblastoma xenograft - Control 22.875638
GSM967854U87-EV human glioblastoma xenograft - Control 32.874638
GSM967855U87-EV human glioblastoma xenograft - Control 42.806238
GSM967856U87-EV human glioblastoma xenograft - Control 52.8425939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0562742
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0835144
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8802439
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8669439
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8854739
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8823639
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8702539
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.899139
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8940639